Advances in Peptide-Based Cancer Vaccines: Materials, Targeting, and Delivery Strategies

Area of Science:

• Oncology
• Immunology
• Nanotechnology
• Drug Delivery

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are limited by "cold" tumors with low PD-L1 expression and mutational burden.
• Cancer vaccines delivering tumor antigens can prime antigen-specific immunity, potentially enhancing ICI efficacy.
• Peptide-based vaccines face hurdles including immune tolerance, poor antigen delivery/presentation, and immunosuppressive tumor microenvironments.

Purpose of the Study:

• To review recent advancements in peptide-based cancer vaccine design.
• To explore strategies for overcoming challenges in peptide vaccine delivery and efficacy.
• To discuss the potential of these novel vaccines in expanding immunotherapy benefits to refractory cancers.

Main Methods:

• Review of current literature on peptide-based cancer vaccine design.
• Analysis of innovative materials, adjuvants, targeting strategies, and controlled release mechanisms.
• Discussion of translational aspects and clinical potential.

Main Results:

• Emerging platforms focus on co-delivering antigens with immunostimulatory agents to enhance immunogenicity.
• Novel materials and controlled release systems aim to improve antigen delivery and presentation.
• Targeting strategies and advanced adjuvants are being developed to overcome tumor microenvironment suppression.

Conclusions:

• Advanced peptide-based cancer vaccines hold significant promise for improving immunotherapy outcomes.
• These strategies may overcome key barriers to effective cancer vaccination and ICI therapy.
• Further development and translation could extend immunotherapy benefits to a broader patient population, including those with treatment-refractory cancers.